The government seeks make it easier for cancer patients to use experimental drugs; a federal judge says the FDA can regulate stem cell companies; US senators reveal a list of 400 troubled nursing homes.
The FDA seeks to facilitate the process for granting cancer patients “compassionate use” access to experimental drugs which have shown promising results in studies but aren’t currently available to the public, according to The New York Times. Yesterday, at the 2019 American Society of Clinical Oncology’s Annual Meeting in Chicago, the FDA announced a project to have the agency serve as a middleman. This would allow physicians to avoid having to first plead their case to companies, then to the agency if the company agrees to provide the drug. Instead, contacting the FDA would become the initial step, then the agency would assign a staffer to quickly complete required paperwork.
US District Court Judge Ursula Ungaro ruled in favor of the FDA yesterday in a lawsuit against US Stem Cell, a Florida-based, for-profit company whose treatments previously blinded 4 patients, The Washington Post reported. Ungaro agreed the FDA has the authority to regulate a widespread procedure that uses fat from patients to create a stem cell treatment and ruled the FDA is entitled to an injunction ordering the company to stop the procedures. The ruling represents a victory for the government, which has struggled to constrain the growing industry.
US senators Bob Casey, D-Pennsylvania, and Pat Toomey, R-Pennsylvania, released a list, provided to them by CMS, of nursing homes with a “persistent record of poor care” whose names weren’t previously disclosed to the public by the government, The New York Times reported. The list identified almost 400 facilities across the nation with documented problems that weren’t included on a shorter list of nursing homes that faced increased federal scrutiny and had warning labels. According to the senators, the secrecy undermines the federal commitment to ensure transparency for families seeking facilities for their family members and raises questions about why the names of some problematic homes were disclosed while others weren’t.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More